Global Point-of-care Glucose Testing Market

Point-of-care Glucose Testing Market Size, Share, Growth Analysis, By Prescription(OTC testing, and Prescription-based testing), By End-use(Hospitals, Diagnostic centers) - Industry Forecast 2024-2031

Report ID: SQMIG15E2398 | Region: Global | Published Date: March, 2024
Pages: 184 | Tables: 64 | Figures: 75

Share your requirements to help us to customize the report.
   I acknowledge that I have read the Privacy Policy
Confidentiality

We respect your privacy rights and safeguard your personal information. We prevent the disclosure of personal information to third parties.

Analyst Support
$5,300
BUY NOW GET FREE SAMPLE

FAQs

Point-of-Care glucose testing Market size was valued at USD 3.3 billion in 2022 and is poised to grow from USD 3.44 billion in 2023 to USD 4.78 billion by 2031, at a CAGR of 4.2% during the forecast period (2024-2031).

The point-of-care glucose testing market is a highly competitive landscape with the presence of several key players. These companies strive to maintain their market position by focusing on product innovation, strategic partnerships, and geographical expansion. Key players in the competitive landscape of the point-of-care glucose testing market continuously strive to introduce advanced technologies, improve product efficacy, and enhance user experience. They also engage in strategic partnerships, mergers, and acquisitions to strengthen their market position and expand their geographical presence. With a focus on innovation and customer-centric approaches, these companies contribute significantly to the growth and development of the point-of-care glucose testing market. 'Abbott (US)', 'Dexcom (US)', 'Roche (Switzerland)', 'Ascensia Diabetes Care (Switzerland)', 'LifeScan (US)', 'Medtronic (US)', 'Ypsomed (Switzerland)', 'Animas (US)', 'Insulet (US)', 'Bayer (Germany)', 'Nipro (Japan)', 'Terumo (Japan)', 'Arkray (Japan)', 'Acon Laboratories (US)', 'Freestyle (US)', 'One Touch (US)', 'Accu-Chek (Germany)', 'Dario (US)', 'iHealth (China)', 'FreeStyle Libre (UK)'

The increasing incidence of diabetes is a major driver of the point-of-care glucose testing market. According to the International Diabetes Federation, the number of adults living with diabetes is expected to reach 700 million by 2045. This surge in diabetes cases necessitates regular glucose monitoring, leading to a higher demand for point-of-care testing devices.

Integration with Digital Health Platforms: The integration of point-of-care glucose testing devices with digital health platforms and electronic health records is a significant trend in 2022. This integration enables seamless data transfer, analysis, and real-time monitoring of glucose levels. It empowers patients to actively participate in their diabetes management and allows healthcare professionals to make informed treatment decisions based on comprehensive patient data.

North America holds the largest market share in the point-of-care glucose testing market. This dominance can be attributed to several factors, including the high prevalence of diabetes in the region, well-established healthcare infrastructure, and favorable reimbursement policies. The presence of key market players, technological advancements, and the adoption of innovative glucose testing devices contribute to the region's leadership position. Additionally, increasing awareness among healthcare professionals and patients about the benefits of point-of-care glucose testing drives market growth in North America.

Related Reports

Oleoresin Market
Buy Now GET FREE SAMPLE
U.S. Institutional Cleaning Ingredients Market
Buy Now GET FREE SAMPLE
Ketones Market
Buy Now GET FREE SAMPLE
Graphene Nanoplatelets Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Point-of-care Glucose Testing Market

Product ID: SQMIG15E2398

$5,300
BUY NOW GET FREE SAMPLE